Tagrisso helps treat a form of lung cancer, while Lenvima can help treat a range of cancers, including thyroid, liver or kidney cancers.
Receiving either of the two drugs also provides members access to the payer’s Oncology Center of Excellence, which connects patients with patient advocates and specialty pharmacists.
“We are honored to be able to dispense these therapies and offer differentiated service and experience to patients through our Oncology Center of Excellence,” said Natalie Bedford, senior vice president of Humana Specialty Pharmacy. “At Humana Specialty Pharmacy, we are committed to providing a holistic and personal health care experience for all of the patients we serve, to drive overall better health outcomes.”
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
